Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 3
2007 1
2008 1
2009 2
2010 4
2011 2
2013 5
2014 1
2015 1
2016 5
2017 13
2018 11
2019 7
2020 23
2021 18
2022 14
2023 24
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Results by year

Filters applied: . Clear all
Page 1
Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors.
Ruf T, Kramer R, Forschner A, Leiter U, Meier F, Reinhardt L, Dücker P, Ertl C, Tomsitz D, Tietze JK, Gutzmer R, Dabrowski E, Zimmer L, Gesierich A, Zierold S, French LE, Eigentler T, Amaral T, Heinzerling L. Ruf T, et al. Among authors: forschner a. Eur J Cancer. 2024 Mar 27;203:114028. doi: 10.1016/j.ejca.2024.114028. Online ahead of print. Eur J Cancer. 2024. PMID: 38652976 Free article.
Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.
Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, Váraljai R, Lodde G, Placke JM, Krefting F, Zaremba A, Ugurel S, Roesch A, Schulz C, Berking C, Pöttgen C, Menzies AM, Long GV, Dummer R, Livingstone E, Schadendorf D, Zimmer L. Albrecht LJ, et al. Among authors: forschner a. Eur J Cancer. 2024 May;202:113976. doi: 10.1016/j.ejca.2024.113976. Epub 2024 Mar 1. Eur J Cancer. 2024. PMID: 38484692 Free article.
Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB.
Amaral T, Nanz L, Stadler R, Berking C, Ulmer A, Forschner A, Meiwes A, Wolfsperger F, Meraz-Torres F, Chatziioannou E, Martus P, Flatz L, Garbe C, Leiter U. Amaral T, et al. Among authors: forschner a. Eur J Cancer. 2024 Apr;201:113912. doi: 10.1016/j.ejca.2024.113912. Epub 2024 Feb 10. Eur J Cancer. 2024. PMID: 38368742 Free article.
The side effect registry immuno-oncology (SERIO) - A tool for systematic analysis of immunotherapy-induced side effects.
Ertl C, Ruf T, Mentzer D, Kong M, Kramer R, Bergwelt-Baildon MV, Subklewe M, Tomsitz D, Ascierto PA, Dummer R, Gogas H, Lebbé C, Long GV, McArthur G, Neilan TG, Ribas A, Robert C, Schadendorf D, Zimmer L, Eigentler T, Grabbe S, Forschner A, Kähler KC, Milani V, Pföhler C, Hassel J, Gutzmer R, Loquai C, Routy B, Furness AJS, Blank C, Wolchok JD, French LE, Hauschild A, Heinzerling L. Ertl C, et al. Among authors: forschner a. Eur J Cancer. 2024 Mar;199:113505. doi: 10.1016/j.ejca.2023.113505. Epub 2023 Dec 23. Eur J Cancer. 2024. PMID: 38262306
Histopathologic regression in patients with primary cutaneous melanoma undergoing sentinel lymph node biopsy is associated with favorable survival and, after metastasis, with improved progression-free survival on immune checkpoint inhibitor therapy: A single-institutional cohort study.
Wagner NB, Knierim SM, Luttermann F, Metzler G, Yazdi AS, Bauer J, Gassenmaier M, Forschner A, Leiter U, Amaral T, Garbe C, Eigentler TK, Forchhammer S, Flatz L. Wagner NB, et al. Among authors: forschner a. J Am Acad Dermatol. 2024 Apr;90(4):739-748. doi: 10.1016/j.jaad.2023.11.040. Epub 2023 Dec 1. J Am Acad Dermatol. 2024. PMID: 38043594 Free article.
Baseline metastatic growth rate is an independent prognostic marker in patients with advanced BRAF V600 mutated melanoma receiving targeted therapy.
Wagner NB, Lenders MM, Kühl K, Reinhardt L, Fuchß M, Ring N, Stäger R, Zellweger C, Ebel C, Kimeswenger S, Oellinger A, Amaral T, Forschner A, Leiter U, Klumpp B, Hoetzenecker W, Terheyden P, Mangana J, Loquai C, Cozzio A, Garbe C, Meier F, Eigentler TK, Flatz L. Wagner NB, et al. Among authors: forschner a. Eur J Cancer. 2024 Jan;196:113425. doi: 10.1016/j.ejca.2023.113425. Epub 2023 Nov 21. Eur J Cancer. 2024. PMID: 38039778 Free article.
[Neues ADO-Komitee "Survivorship"].
Forschner A, Zimmer L. Forschner A, et al. J Dtsch Dermatol Ges. 2023 Oct;21(10):1266-1267. doi: 10.1111/ddg.15208_g. J Dtsch Dermatol Ges. 2023. PMID: 37845078 German. No abstract available.
131 results